A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically confirmed colorectal adenocarcinoma that contains MSS and BRAF V600E mutation * Metastatic inoperable colorectal cancer * Adequate function of hematopoiesis and basic indicators of internal organs * Has measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors (RECIST v1.1). * Lacking antitumor systemic treatment for colorectal cancer. * Patients with progression after adjuvant chemotherapy may be included if progression is recorded no earlier than 12 months after the last course of chemotherapy. * The primary tumor is removed or asymptomatic. * Absence of grade 2 or higher neuropathy. * Absence of tumor MSI or dMMR. * ECOG PS 0-2 Exclusion Criteria: * Participants having more than 2 lines of treatment (a progression of disease within 12 months of the completion of adjuvant and/or perioperative chemotherapy with oxaliplatin and fluoropyrimidines is acceptable). * Presence of any other malignancy, except radically treated basal cell carcinoma, cervical cancer in situ, currently or within 5 years prior to enrolment. * Pregnant and breastfeeding women. * Male and female patients with preserved reproductive potential who refused to use adequate contraception throughout the study. * HIV-infected patients. * Patients with a life expectancy of less than 3 months. * The presence of a disease or condition that, in the opinion of the investigator, prevents the patient from participating in the trial.